# ALC catalysts: ALCON INC PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/alc/catalysts

> ALCON INC (ALC) has 2 upcoming catalysts. The next is the apraclonidine ophthalmic solution, 0.125% unit dose preservative free primary completion, February 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ALCON INC |
| Ticker | ALC (NYSE) |
| SEC CIK | 1167379 |
| SIC | 3851 |
| SEC filings | https://sec-api.dev/companies/alc |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| February 29, 2016 | [Tetracaine Hydrochloride (tetracaine hydrochloride) FDA approval](https://sec-api.dev/pdufa/tetracaine) | ALC |  | completed, approved | "NDA208135 ORIG-1 (Type 7 - Drug Already Marketed without Approved NDA): submission_status AP, submission_status_date 20160229, review_priority STANDARD; sponsor_name ALCON LABS; product TETRACAINE HYDROCHLORIDE (TETRACAINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208135%22)) |
| December 1, 2016 | [Atropine Sulfate (atropine sulfate) FDA approval](https://sec-api.dev/pdufa/atropine) | ALC |  | completed, approved | "NDA208151 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20161201, review_priority STANDARD; sponsor_name ALCON LABS INC; product ISOPTO ATROPINE (ATROPINE SULFATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208151%22)) |
| December 18, 2017 | [Rhopressa (netarsudil mesylate) FDA approval](https://sec-api.dev/pdufa/netarsudil) | ALC |  | completed, approved | "NDA208254 ORIG-1 (Type 1 - New Molecular Entity): submission_status AP, submission_status_date 20171218, review_priority STANDARD; sponsor_name ALCON LABS INC; product RHOPRESSA (NETARSUDIL MESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208254%22)) |
| August 22, 2018 | [Eysuvis (loteprednol etabonate) FDA approval](https://sec-api.dev/pdufa/loteprednol-etabonate) | ALC |  | completed, approved | "NDA210565 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20180822, review_priority STANDARD; sponsor_name ALCON LABS INC; product INVELTYS (LOTEPREDNOL ETABONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210565%22)) |
| March 12, 2019 | [Rocklatan (latanoprost; netarsudil dimesylate) FDA approval](https://sec-api.dev/pdufa/latanoprost-netarsudil) | ALC |  | completed, approved | "NDA208259 ORIG-1 (New Combination and New Formulation or New Manufacturer): submission_status AP, submission_status_date 20190312, review_priority STANDARD; sponsor_name ALCON LABS INC; product ROCKLATAN (LATANOPROST; NETARSUDIL DIMESYLATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA208259%22)) |
| February 14, 2020 | [Pataday Twice Daily Relief (olopatadine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/olopatadine) | ALC |  | completed, approved | "NDA020688 SUPPL-32 (Efficacy): submission_status AP, submission_status_date 20200214, review_priority STANDARD; sponsor_name ALCON LABS INC; product PATADAY TWICE DAILY RELIEF (OLOPATADINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA020688%22)) |
| July 13, 2020 | [Pataday Twice Daily Relief (olopatadine hydrochloride) label expansion decision](https://sec-api.dev/pdufa/olopatadine) | ALC |  | completed, approved | "NDA206276 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20200713, review_priority STANDARD; sponsor_name ALCON LABS INC; product PATADAY ONCE DAILY RELIEF (OLOPATADINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA206276%22)) |
| October 26, 2020 | [Eysuvis (loteprednol etabonate) FDA approval](https://sec-api.dev/pdufa/loteprednol-etabonate) | ALC |  | completed, approved | "NDA210933 ORIG-1 (Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated): submission_status AP, submission_status_date 20201026, review_priority STANDARD; sponsor_name ALCON LABS INC; product EYSUVIS (LOTEPREDNOL ETABONATE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA210933%22)) |
| May 28, 2025 | [Tryptyr (acoltremon) FDA approval](https://sec-api.dev/pdufa/acoltremon) | ALC | To treat the signs and symptoms of dry eye disease | completed, approved | "Tryptyr \| acoltremon \| 5/28/2025 \| To treat the signs and symptoms of dry eye diseaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)) |
| November 14, 2025 | [Ar-17043 ophthalmic solution primary completion](https://sec-api.dev/pdufa/ar-17043) | ALC | Open Angle Glaucoma; Ocular Hypertension | completed | "NCT06441643 (Next Generation Rocklatan): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-11-14 (ACTUAL); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06441643)) |
| April 6, 2026 | [Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution primary completion](https://sec-api.dev/pdufa/netarsudil-0-01-latanoprost-0-005) | ALC | Ocular Hypertension; Open Angle Glaucoma | completed | "NCT07082816 (Reformulated PG324 Ophthalmic Solution for Intraocular Pressure Reduction): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-04-06 (ACTUAL); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07082816)) |
| October 16, 2026 | [Brytly (apraclonidine hydrochloride) FDA approval](https://sec-api.dev/pdufa/apraclonidine) | ALC |  | completed, approved | "NDA220341 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20261016, review_priority STANDARD; sponsor_name ALCON LABS INC; product BRYTLY (APRACLONIDINE HYDROCHLORIDE)." ([openFDA Drugs@FDA](https://api.fda.gov/drug/drugsfda.json?search=application_number:%22NDA220341%22)) |
| November 2026 | [Apraclonidine ophthalmic solution, 0.125% unit dose preservative free primary completion](https://sec-api.dev/pdufa/apraclonidine-ophthalmic-solution-0-125-unit-dose-preservative-free) | ALC | Ocular Hyperemia | scheduled | "NCT07578363 (An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578363)) |
| Nov 2026 to Feb 2027 | [Apraclonidine ophthalmic solution, 0.125% unit dose preservative free topline data readout](https://sec-api.dev/pdufa/apraclonidine-ophthalmic-solution-0-125-unit-dose-preservative-free) | ALC | Ocular Hyperemia | scheduled | "NCT07578363 (An Investigation of FID 123472 Ophthalmic Solution to Vehicle for the Reduction of Ocular Redness in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-11 (ESTIMATED); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07578363)) |
| February 2027 | [Apraclonidine ophthalmic solution, 0.125% unit dose preservative free primary completion](https://sec-api.dev/pdufa/apraclonidine-ophthalmic-solution-0-125-unit-dose-preservative-free) | ALC | Ocular Hyperemia | scheduled | "NCT07531043 (Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07531043)) |
| Feb to May 2027 | [Apraclonidine ophthalmic solution, 0.125% unit dose preservative free topline data readout](https://sec-api.dev/pdufa/apraclonidine-ophthalmic-solution-0-125-unit-dose-preservative-free) | ALC | Ocular Hyperemia | scheduled | "NCT07531043 (Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-02 (ESTIMATED); Lead Sponsor Alcon Research." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07531043)) |

## Drugs

- [Tryptyr (acoltremon)](https://sec-api.dev/pdufa/acoltremon): To treat the signs and symptoms of dry eye disease
- [Brytly (apraclonidine hydrochloride)](https://sec-api.dev/pdufa/apraclonidine): 
- [Apraclonidine ophthalmic solution, 0.125% unit dose preservative free](https://sec-api.dev/pdufa/apraclonidine-ophthalmic-solution-0-125-unit-dose-preservative-free): Ocular Hyperemia
- [Ar-17043 ophthalmic solution](https://sec-api.dev/pdufa/ar-17043): Open Angle Glaucoma
- [Rocklatan (latanoprost; netarsudil dimesylate)](https://sec-api.dev/pdufa/latanoprost-netarsudil): 
- [Eysuvis (loteprednol etabonate)](https://sec-api.dev/pdufa/loteprednol-etabonate): 
- [Rhopressa (netarsudil mesylate)](https://sec-api.dev/pdufa/netarsudil): 
- [Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution](https://sec-api.dev/pdufa/netarsudil-0-01-latanoprost-0-005): Ocular Hypertension
- [Pataday Twice Daily Relief (olopatadine hydrochloride)](https://sec-api.dev/pdufa/olopatadine): 
- [Tetracaine Hydrochloride (tetracaine hydrochloride)](https://sec-api.dev/pdufa/tetracaine): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/alc/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "ALC catalysts: ALCON INC PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/alc/catalysts

```bibtex
@misc{secapidev_companies_alc_catalysts_20261116,
  title        = {ALC catalysts: ALCON INC PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/alc/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_alc_catalysts_20261116","title":"ALC catalysts: ALCON INC PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/alc/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
